Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis.
Melanogenesis generates immunosuppressive and mutagenic environment and alters cellular metabolism. Melanin can protect malignant melanocytes against chemo-, radio-, and photodynamic therapy. Therefore, we propose to inhibit melanogenesis as an adjuvant treatment modality during immuno-, radio-, chemo- and photodynamic therapy, and as a measure of reducing the probability of melanoma progression.
Slominski
A
A
Department of Pathology, Loyola University Medical Center, Maywood, IL. aslomin@wpo.it.luc.edu
Paus
R
R
Mihm
M C
MC
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001973:Bromodeoxyuridine / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D006801:Humans; D008543:Melanins / Q000096:biosynthesis* / Q000494:pharmacology; D008544:Melanocytes / Q000187:drug effects*; D008545:Melanoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy; D010778:Photochemotherapy; D020011:Protective Agents / Q000494:pharmacology
D000964:Antimetabolites, Antineoplastic; D008543:Melanins; D020011:Protective Agents; D001973:Bromodeoxyuridine